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Purpose: To analyze choroidal thickness (CT) of pregnant women with type 1 diabetes 
mellitus (DM), type 2 DM and gestational diabetes mellitus (GDM) using spectral-domain 
optical coherence tomography.
Patients and methods: This cross-sectional study included 144 eyes of 72 pregnant women 
in the third trimester divided into four groups: 27 non-diabetic pregnant women; 15 pregnant 
women with GDM; 16 with type 2 DM and 14 with type 1 DM. CT was measured using optical 
coherence tomography at ten different locations. We also analyzed possible confounding fac-
tors, such as gestational age, glycosylated hemoglobin, time from DM diagnosis, hypertension 
and severity of diabetic retinopathy. 
Results: The comparison between the four groups showed a thinner choroid in patients with 
type 1 DM in all locations, with statistical significance in subfoveal and temporal measure-
ments. When comparing only patients with type 1 and type 2 DM, adjusting for confounding 
factors, the choroid of patients with type 1 DM remained thinner at all macular points, also with 
statistical significance in subfoveal and temporal measurements. 
Conclusion: Pregnant women with type 1 DM had significantly thinner CT measurements on 
subfoveal and temporal locations. No differences were found in CT between the control group 
and pregnant women with GDM and type 2 DM.
Keywords: choroid, enhanced depth imaging optical coherence tomography, pregnancy, 
gestational diabetes mellitus, diabetes mellitus
Introduction
Diabetic retinopathy (DR) is a major cause of visual impairment in women during 
their childbearing years. It is known that pregnancy is an independent risk factor for 
DR progression,1–3 and its implications can persist for the first year after delivery. 
Other risk factors include glycemic control, duration of diabetes, baseline level of DR, 
hypertension and preeclampsia.4,5 Previous reports, however, suggest that rapid opti-
mization in glucose control may result in an increased risk for the progression of DR 
during pregnancy.3,4
The reasons why pregnancy itself causes a worsening in DR are still being ques-
tioned. A possible relation with morphological changes of the choroid should be 
studied. Diabetic choroidopathy, first reported by Hidayat and Fine in 1985,6 might 
be present before the onset of DR.7 Several choroidal changes have been described 
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in diabetic patients, including microaneurysms, dilatation 
and obstruction of the choriocapillaris, increased vascular 
tortuosity, vascular dropouts, areas of vascular non-perfusion 
and choroidal neovascularization.8 
The development of the enhanced depth imaging (EDI) 
technique of spectral-domain optical coherence tomography 
(SD-OCT) systems have allowed adequate analysis of chor-
oidal morphologic features in normal and pathological eyes.9 
EDI-OCT dramatically increases image resolution of the 
choroid by decreasing signal strength posterior to the retinal 
pigment epithelium. Although many authors have reported 
a decrease in choroidal thickness (CT) among diabetic 
patients,10–15 there are some discordant studies.7,16,17
The presence of choroidal changes related to pregnancy 
is also being investigated. The strong correlation between 
central serous chorioretinopathy (CSC) and pregnancy is well 
documented.18,19 Choroidal dysfunction and ischemia are also 
a common ocular complication of preeclampsia.20–22 Since 
it is a noninvasive diagnostic method, OCT is ideal for the 
study of choroidal changes in pregnant women. Some studies 
have already analyzed CT in healthy pregnant women using 
OCT,23–28 but the results are still inconclusive. 
The aim of this study was to analyze CT measurements 
of non-diabetic pregnant women and of pregnant women 
with type 1, type 2 and gestational diabetes mellitus (GDM) 
using SD-OCT.
Patients and methods
This cross-sectional study included 144 eyes of 72 preg-
nant women in the third trimester divided into four groups: 
Group 1 consisted of 27 non-diabetic pregnant women 
(control group); Group 2 consisted of 15 pregnant women 
with GDM; Group 3 consisted of 16 pregnant women with 
type 2 diabetes mellitus (type 2 DM) and Group 4 consisted 
of 14 pregnant women with type 1 diabetes mellitus (type 1 
DM). The participants were recruited between March and 
September 2016 at the Hospital de Clinicas de Porto Alegre 
(HCPA), Brazil. All participants received in person a full 
explanation about the study and provided written informed 
consent. This study was approved by the HCPA research 
ethics committee and was conducted in accordance with the 
Declaration of Helsinki guidelines.
All participants were receiving prenatal care at HCPA 
and were in their third trimester of singleton pregnancy. Sub-
jects with a history of laser photocoagulation, anti-vascular 
endothelial growth factor (VEGF) treatment, ocular surgery 
or any ocular pathology except for DR were excluded. 
Refractive disorders with spherical equivalent greater than 
±1.0 diopters, intraocular pressure higher than 21 mmHg or 
best-corrected visual acuity worse than 0,1 logMAR were 
also exclusion criteria. Participants with preeclampsia, 
multiple pregnancies, renal or rheumatological diseases or 
history of smoking were also excluded. 
The criteria used for GDM diagnosis followed the Inter-
national Association of Diabetes in Pregnancy Study Groups 
(IADPSG) recommendations.29 We analyzed the glycosylated 
hemoglobin A1c (HbA1c) of all diabetic patients; the blood 
samples for HbA1c were collected within 30 days of the 
ophthalmic exam. DR grading was performed according 
to the international severity scale:30 mild nonproliferative 
DR (microaneurysms only); moderate nonproliferative DR 
(more than just microaneurysms but less than severe non-
proliferative DR); severe nonproliferative DR (more than 
20 intraretinal hemorrhages in each of four quadrants or 
venous beading in two quadrants or prominent intraretinal 
microvascular abnormalities in 1 quadrant) and proliferative 
DR (neovascularization or vitreous/preretinal hemorrhage). 
The diagnosis for each individual was based on the grading 
of the worse eye per subject. Only treatment-naive patients 
were included.
All study participants underwent an interview with demo-
graphic and background history. The ophthalmic examination 
included uncorrected visual acuity, best-corrected visual 
acuity, Goldmann applanation tonometry, slit-lamp assisted 
biomicroscopy, indirect ophthalmoscopy and SD-OCT. 
All OCT scans were performed in the morning (8:00 am 
to 12:00 pm) to avoid diurnal variations of CT. The same 
experienced ophthalmologist (CB) performed all ophthalmic 
examinations and OCT scans, using Heidelberg Spectralis 
OCT (Heidelberg Engineering Co, Heidelberg, Germany). 
Choroid was imaged with a 6-line radial scan (30°, 9.2 mm) 
using the EDI setting, with 100 images averaged per section. 
All scans were reviewed before being included in the study. 
Those with image artefacts or inaccurate choroidal limits 
were excluded. 
CT was determined as the vertical distance from the 
outer surface of the line formed by the retinal pigment 
epithelium to the chorioscleral interface using the Spectra-
lis OCT measurement software. The measurements were 
made by an experienced ophthalmologist (DL) masked 
to the participant group. Previous studies have already 
demonstrated the reproducibility of this technique, even 
across different OCT systems.31–33 CT was measured at ten 
different locations: at the fovea and every 500 µm from 
the fovea up to 2,500 µm temporally and up to 2,000 µm 
nasally (Figure 1). We used the following abbreviations 
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for the macular points: T5: CT at 2,500 µm temporally to 
the fovea; T4: CT at 2,000 µm temporally to the fovea; T3: 
CT at 1,500 µm temporally to the fovea; T2: CT at 1,000 
µm temporally to the fovea; T1: CT at 500 µm temporally 
to the fovea; SF: CT at the fovea; N1: CT at 500 µm nasally 
to the fovea; N2: CT at 1,000 µm nasally to the fovea; N3: 
CT at 1,500 µm nasally to the fovea and N4: CT at 2,000 
µm nasally to the fovea.
statistical analysis
Statistical analyses were performed using SPSS V.15.0 
(SPSS Science, Chicago, IL, USA). Quantitative variables 
were presented as mean (±SD) or median and interquartile 
range. Categorical variables were described by absolute 
and relative frequencies. To compare means between 
groups, analysis of variance (ANOVA) complemented by 
Tukey was applied. In case of asymmetry, Mann–Whitney 
and Kruskal–Wallis tests were used. For qualitative data, 
a chi-squared test was used. Differences in CT were ana-
lyzed using generalized estimating equations (GEE) with 
Bonferroni adjustment. A p-value #0.05 was considered 
statistically significant.
Results
The demographic and clinical characteristics of the subjects 
are summarized in Table 1. The OCT scans were per-
formed in 54 eyes of 27 healthy pregnant women, 30 eyes 
of 15 pregnant women with GDM, 32 eyes of 16 pregnant 
women with type 2 DM and 28 eyes of 14 pregnant women 
with type 1 DM. There was no significant difference in 
age, ethnicity and gestational age between groups. As 
expected, time from DM diagnosis was significantly higher 
in subjects with type 1 DM in comparison with subjects 
with type 2 DM. HbA1c values were significantly higher 
Figure 1 Measurements of choroidal thickness at 10 locations.
?????? ??????
?????? ?????? ?????? ?????? ?????? ?????? ?????? ??????
?????? ??????
Table 1 Demographic and clinical characteristics of the study and control groups
Clinical features Nondiabetic 
group (n=27)
GDM group 
(n=15)
Type 2 DM 
group (n=16)
Type 1 DM 
group (n=14)
p-value
age (years)
Mean ± sD
28.1 ± 7.0 31.9 ± 5.8 31.4 ± 6.0 28.1 ± 6.6 0.177a
ethnicity, n (%)
Caucasian
african-american
25 (92.6)
2 (7.4)
10 (66.7)
5 (33.3)
13 (81.3)
3 (18.8)
13 (92.9)
1 (7.1)
0.209b
gestational age
(weeks)
Mean ± sD
33.3 ± 2.6 33.7 ± 3.19 32.0 ± 3.6 31.7 ± 3.0 0.183a
Time from DM diagnosis (years)
Median (P25–P75)
1.5 (0.9–4.5) 13.5 (5–20) ,0.001c
hba1c (%)
Mean ± sD
5.7 ± 0.8a 6.6 ± 1.7a,b 7.4 ± 1.2b 0.006a
hypertension,
n (%)
0 (0) 2 (13.3) 6 (37.5) 0 (0) 0.001b
Diabetic retinopathy,
n (%)
1 (6.3%) 6 (42.9%) 0.031d
Notes: aanalysis of variance (anOVa); bChi-squared test; cMann–Whitney test; a,b same letter does not differ from each other at a 5% of significance by Tukey test; dFisher’s 
exact test. 
Abbreviations: DM, diabetes mellitus; gDM, gestational diabetes mellitus.
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in patients with type 1 DM (7.4% ± 1.2%) compared with 
GDM patients (5.7% ± 0.8%) ( p=0.06). Two patients 
from group 2 and six patients from group 3 had chronic 
hypertension diagnosis (p=0.001), requiring adjustment in 
CT analysis.
Of the 14 subjects with type 1 DM, 6 (42.9%) were 
diagnosed with DR (1 mild nonproliferative, 4 moderate 
nonproliferative and 1 proliferative DR). In comparison, 
only one patient (6.3%) with type 2 DM was diagnosed with 
moderate nonproliferative retinopathy (p=0.031). None of 
the subjects with DR had macular edema on OCT and all of 
them were treatment-naive at the time of the exam.
Comparing the 10 CT measurements of the four groups, 
adjusted for the presence of hypertension, the choroid always 
tended to be thinner in patients with type 1 DM. There was 
no significant differences between nondiabetic, GDM and 
type 2 DM groups. From macular points T5 to T1, macular 
thickness was significantly higher in pregnant women with 
GDM in comparison with pregnant women with type 1 DM. 
In the subfoveal measurement, however, macular thickness 
was significantly higher in pregnant women with type 2 
DM in comparison with pregnant women with type 1 DM. 
No measures nasal to the fovea were statistically different 
between the groups. All measurements and p-values  are 
shown in Table 2.
When we analyzed only the groups with diabetic 
patients, adjusting also for HbA1c levels, the choroid 
was thinner in patients with type 1 DM in comparison 
with patients with GDM or type 2 DM (Table 3). CT 
measurements in T5, T3, T2, T1 and SF macular points 
were significantly thinner in patients with type 1 DM 
in comparison with patients with GDM and type 2 DM. 
The choroid in T4 and N1 macular points, however, was 
significantly thinner in patients with type 1 DM only in 
comparison with patients with DMG. No statistically sig-
nificant difference between groups was found at the N2, 
N3 and N4 macular points.
In order to analyze CT adjusting also for time of DM 
diagnosis and presence of DR, we also performed an analy-
sis only between the type 1 DM and type 2 DM groups 
(Table 4). CT of patients with type 1 DM remained thin-
ner than in patients with type 2 DM at all macular points, 
but with statistical significance only in T4, T3, T2, T1 
and SF points.
Discussion
The choroid is a complex vascular network which provides 
vascular supply for the retinal pigment epithelium and outer 
retina layers, representing the sole provider of oxygen and 
nutrients to the avascular fovea. This vascular network is 
responsible for more than 85% of the blood flow in the eye. 
Unlike the retina, autoregulation of choroidal blood flow is 
limited and it has intense autonomic innervation. Abnormal 
choroidal blood flow can result in photoreceptor dysfunction 
and death.34,35
CT is influenced by major factors such as age, refrac-
tive error and axial length (AL), with increasing age, AL 
and decreasing refractive diopter being associated with a 
reduction of CT.36 Diurnal variations in CT have also been 
reported.37,38 Although choroidal thickness has more precise 
characteristics in some diseases such as CSC and age-related 
macular degeneration (AMD), choroidal changes in diabetic 
patients have been studied and controversial results have 
been published. 
Table 2 Comparison of CT measurements of all groups; adjusted for the presence of hypertension
Location Nondiabetic 
group (n=27), 
mean ± SE (µm)
GDM group (n=15),  
mean ± SE (µm)
Type 2 DM 
group (n=16), 
mean ± SE (µm)
Type 1 DM 
group (n=14), 
mean ± SE (µm)
p-value 
(adjusted for 
hypertension)
T5 250.9 ± 16.3a,b 260.2 ± 12.7b 242.4 ± 11.2a,b 212.7 ± 15.1a 0.049
T4 269.4 ± 18.0a,b 273.4 ± 15.4b 252.9 ± 12.1a,b 226.6 ± 14.1a 0.026
T3 277.8 ± 16.4b 283.5 ± 15.7b 274.9 ± 10.2a,b 232.2 ± 12.2a 0.007
T2 283.9 ± 17.7a,b 294.5 ± 16.7b 288.8 ± 12.2a,b 240.6 ± 14.7a 0.015
T1 287.1 ± 18.4a,b 304.8 ± 17.4b 304.3 ± 14.3a,b 248.2 ± 15.6a 0.014
sF 293.9 ± 19.0a,b 311.3 ± 19.6a,b 318.4 ± 14.0b 255.1 ± 15.5a 0.014
n1 267.2 ± 20.2 294.3 ± 23.4 291.7 ± 16.2 242.7 ± 16.3 0.067
n2 243.4 ± 19.0 274.3 ± 20.9 282.8 ± 14.9 231.7 ± 15.1 0.106
n3 217.6 ± 17.6 242.1 ± 18.7 257.2 ± 14.4 218.6 ± 14.7 0.338
n4 190.0 ± 15.6 222.9 ± 18.2 227.0 ± 12.6 191.5 ± 13.5 0.190
Note: a,bSame letter does not differ from each other at a 5% of significance by GEE with Bonferroni adjustment. 
Abbreviations: CT, choroidal thickness; DM, diabetes mellitus; gDM, gestational diabetes mellitus; n1, choroidal thickness at 500 µm nasal to the fovea; gee, 
generalized estimating equations; n2, choroidal thickness at 1,000 µm nasal to the fovea; n3, choroidal thickness at 1,500 µm nasal to the fovea; n4, choroidal thickness 
at 2,000 µm nasal to the fovea; sF, choroidal thickness at the fovea; T1, choroidal thickness at 500 µm temporal to the fovea; T2, choroidal thickness at 1,000 µm 
temporal to the fovea; T3, choroidal thickness at 1,500 µm temporal to the fovea; T4, choroidal thickness at 2,000 µm temporal to the fovea; T5, choroidal thickness 
at 2,500 µm temporal to the fovea.
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Recent studies conducted by Yazici et al7 and Tavares 
Ferreira et al16 found that the choroid is thicker in diabetic 
patients. The population-based Beijing Eye study17 also 
found that DM can lead to a slight thickening of the chor-
oid, although not related to the severity of DR. Yulek et al 
concluded that subfoveal CT was not significantly corre-
lated with increased duration of diabetes.39 Regatieri et al,10 
however, reported a thinner CT in patients with diabetic 
macular edema or treated proliferative DR compared with 
normal subjects. Vujosevic et al,11 Esmaeelpour et al,12,13 
Querques et al14 and Shen et al15 also demonstrated that 
CT decreases in diabetic eyes with clinical signs of DR 
compared with controls. 
The aim of this study was to analyze these possible 
changes in CT in diabetic patients during pregnancy. Since 
pregnancy is an independent risk factor for the progression 
of DR, we questioned if possible changes in the choroid 
may contribute to this progression. There is limited data on 
this issue and to the best of our knowledge this is the first 
study to compare CT in pregnant women with type 1 and 
type 2 DM. Acmaz et al40 reported that CT was significantly 
thicker in healthy pregnant women and women with GDM 
in comparison with non-pregnant women. However, there 
was no significant difference between the GDM group and 
the healthy pregnant women group.
As pregnancy itself could lead to physiological changes 
in the choroid, our control group consisted of nondiabetic 
pregnant women. In this study, we found no difference in CT 
between non-diabetic pregnant women, women with GDM 
and pregnant women with type 2 DM. Pregnant women with 
type 1 DM, however, had smaller CT measurements at all 
points analyzed. 
This choroid thinning in patients with type 1 DM was 
more significant in the measurements located temporally to 
the fovea. Measurements of CT nasally to the fovea were 
not statistically different. 
Table 3 Comparison of CT measurements of pregnant patients with gDM, type 1 DM and type 2 DM, adjusted for hba1c values and 
for the presence of hypertension
Location GDM group (n=15), 
mean ± SE (µm)
Type 2 DM 
group (n=16), 
mean ± SE (µm)
Type 1 DM 
group (n=14), 
mean ± SE (µm)
p-value (adjusted 
for HbA1c and 
hypertension)
T5 271.5 ± 43.3b 243.5 ± 35.7b 209.4 ± 39.2a 0.002
T4 287.9 ± 47.7b 254.2 ± 38.6a,b 222.4 ± 42.5a 0.001
T3 397.6 ± 59.4b 276.4 ± 56.1b 227.9 ± 51.6a ,0.001
T2 311.7 ± 75.3b 290.4 ± 74.0b 235.5 ± 64.0a 0.001
T1 221.1 ± 77.3b 305.8 ± 76.7b 243.4 ± 66.0a 0.002
sF 327.1 ± 85.9b 319.9 ± 88.9b 250.4 ± 72.6a 0.005
n1 310.5 ± 104.6b 293.2 ± 106.1a,b 237.8 ± 86.1a 0.037
n2 284.1 ± 105.4 284.1 ± 107.4 228.5 ± 86.7 0.081
n3 248.7 ± 100.6 258.4 ± 100.5 216.4 ± 83.3 0.244
n4 223.8 ± 80.5 227.8 ± 77.4 190.8 ± 66.6 0.188
Note: a,bSame letter does not differ from each other at a 5% of significance by GEE with Bonferroni adjustment.
Abbreviations: CT, choroidal thickness; DM, diabetes mellitus; gDM, gestational diabetes mellitus; gee, generalized estimating equations; hba1c, glycosylated hemoglobin 
a1c; n1, choroidal thickness at 500 µm nasal to the fovea; n2, choroidal thickness at 1,000 µm nasal to the fovea; n3, choroidal thickness at 1,500 µm nasal to the fovea; 
n4, choroidal thickness at 2,000 µm nasal to the fovea; sF, choroidal thickness at the fovea; T1, choroidal thickness at 500 µm temporal to the fovea; T2, choroidal thickness 
at 1,000 µm temporal to the fovea; T3, choroidal thickness at 1,500 µm temporal to the fovea; T4, choroidal thickness at 2,000 µm temporal to the fovea; T5, choroidal 
thickness at 2,500 µm temporal to the fovea.
Table 4 Comparison of CT measurements of pregnant patients 
with type 1 DM and type 2 DM; adjusted for hba1c values and 
the presence of hypertension
Location Type 2 DM 
group (n=16), 
mean ± SE (µm)
Type 1 DM 
group (n=14), 
mean ± SE (µm)
p-value (adjusted 
for HbA1c, time 
of DM diagnosis 
and presence 
of diabetic 
retinopathy and 
hypertension)
T5 244.7 ± 86.5 211.2 ± 83.3 0.051
T4 255.6 ± 78.9 221.9 ± 76.2 0.026
T3 274.6 ± 87.8 234.8 ± 75.4 0.034
T2 287.8 ± 112.9 242.6 ± 95.8 0.047
T1 303.5 ± 117.6 248.0 ± 100.9 0.022
sF 320.8 ± 132.1 249.6 ± 110.2 0.007
n1 295.9 ± 155.4 240.3 ± 127.6 0.079
n2 285.2 ± 153.4 225.3 ± 126.9 0.053
n3 260.2 ± 153.9 206.1 ± 129.5 0.083
n4 220.8 ± 122.7 186.6 ± 101.9 0.199
Note: gee with Bonferroni adjustment.
Abbreviations: CT, choroidal thickness; DM, diabetes mellitus; gee, generalized 
estimating equations; hba1c, glycosylated hemoglobin a1c; n1, choroidal thickness 
at 500 µm nasal to the fovea; n2, choroidal thickness at 1,000 µm nasal to the fovea; 
n3, choroidal thickness at 1,500 µm nasal to the fovea; n4, choroidal thickness at 
2,000 µm nasal to the fovea; sF, choroidal thickness at the fovea; T1, choroidal 
thickness at 500 µm temporal to the fovea; T2, choroidal thickness at 1,000 µm 
temporal to the fovea; T3, choroidal thickness at 1,500 µm temporal to the fovea; 
T4, choroidal thickness at 2,000 µm temporal to the fovea; T5, choroidal thickness 
at 2,500 µm temporal to the fovea.
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We also performed this analysis only among diabetic 
patients to enable adjustment for HbA1c, with similar results. 
When we compared only pregnant women with type 1 and 
type 2 diabetes, adjusting also for time of diabetes and pres-
ence of retinopathy, CT remained significantly thinner in 
subjects with type 1 DM between T4 and SF points.
Despite being a controversial subject, most of the 
available evidence seems to indicate that choroid thins in 
diabetic eyes.41 According to our findings, pregnant sub-
jects with type 1 DM also followed this thinning pattern. 
The significantly higher prevalence of DR found in these 
patients may have contributed to this finding. It is possible 
to hypothesize that choroidal thinning in type 1 pregnant 
diabetic patients occurs as part of diabetic choroidopathy 
modifications. The decreased choroidal blood flow found in 
diabetic patients,42–44 along with changes such as atrophy and 
dropout of the choriocapillaris,6,45 could contribute to this 
thinning. It remains to be understood how these ocular blood 
flow abnormalities seen in diabetic patients are influenced by 
pregnancy hyperflow and whether these modifications could 
contribute to the DR progression seen in pregnancy.
Since CT measurements may be susceptible to several 
confounding factors, we tried to minimize possible biases. 
The examinations were performed only in the morning shift 
to avoid diurnal variations, and patients with refractive dis-
orders with spherical equivalent greater than ±1.0 diopters 
were excluded. Exams without clear identification of the 
choroid-scleral junction were also excluded from the analysis. 
Since laser photocoagulation and anti-VEGF treatments may 
change CT,10,41,46 only treatment-naive patients were included. 
None of the subjects with DR had macular edema on OCT.
Our study also has some limitations, such as the small 
number of subjects. Its cross-sectional design allow us to 
analyze choroid characteristics only from the third trimes-
ter of pregnancy. Further prospective studies with a larger 
number of subjects should be performed to confirm these 
findings.
Conclusion
Our study showed no statistically significant difference in CT 
between non-diabetic pregnant women, pregnant women with 
GDM and pregnant women with type 2 DM during the third 
trimester. Pregnant women with type 1 DM had significantly 
thinner CT measurements on subfoveal and temporal to the 
fovea analysis.
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